Intraperitoneal chemotherapy: Phase III trials

David S. Alberts; Mary C. Clouser

doi:10.1007/978-3-642-12130-2_4

Intraperitoneal chemotherapy: Phase III trials

David S. Alberts, Mary C. Clouser

Cancer Center

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].

Original language	English (US)
Title of host publication	Intraperitoneal Therapy for Ovarian Cancer
Publisher	Springer Berlin Heidelberg
Pages	37-50
Number of pages	14
ISBN (Print)	9783642121296
DOIs	https://doi.org/10.1007/978-3-642-12130-2_4
State	Published - Dec 1 2010

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-3-642-12130-2_4

Fingerprint Dive into the research topics of 'Intraperitoneal chemotherapy: Phase III trials'. Together they form a unique fingerprint.

Cite this

Alberts, D. S., & Clouser, M. C. (2010). Intraperitoneal chemotherapy: Phase III trials. In Intraperitoneal Therapy for Ovarian Cancer (pp. 37-50). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-12130-2_4

@inbook{a4000d33784942758e69a3a4715c8c8f,

title = "Intraperitoneal chemotherapy: Phase III trials",

abstract = "It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].",

author = "Alberts, {David S.} and Clouser, {Mary C.}",

year = "2010",

month = dec,

day = "1",

doi = "10.1007/978-3-642-12130-2_4",

language = "English (US)",

isbn = "9783642121296",

pages = "37--50",

booktitle = "Intraperitoneal Therapy for Ovarian Cancer",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Intraperitoneal chemotherapy

T2 - Phase III trials

AU - Alberts, David S.

AU - Clouser, Mary C.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].

AB - It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].

UR - http://www.scopus.com/inward/record.url?scp=84895278070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895278070&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-12130-2_4

DO - 10.1007/978-3-642-12130-2_4

M3 - Chapter

AN - SCOPUS:84895278070

SN - 9783642121296

SP - 37

EP - 50

BT - Intraperitoneal Therapy for Ovarian Cancer

PB - Springer Berlin Heidelberg

ER -